JP2024521754A5 - - Google Patents

Info

Publication number
JP2024521754A5
JP2024521754A5 JP2023572581A JP2023572581A JP2024521754A5 JP 2024521754 A5 JP2024521754 A5 JP 2024521754A5 JP 2023572581 A JP2023572581 A JP 2023572581A JP 2023572581 A JP2023572581 A JP 2023572581A JP 2024521754 A5 JP2024521754 A5 JP 2024521754A5
Authority
JP
Japan
Prior art keywords
seq
gene
slc6a3
low
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023572581A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022251375A5 (https=
JP2024521754A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/030946 external-priority patent/WO2022251375A2/en
Publication of JP2024521754A publication Critical patent/JP2024521754A/ja
Publication of JPWO2022251375A5 publication Critical patent/JPWO2022251375A5/ja
Publication of JP2024521754A5 publication Critical patent/JP2024521754A5/ja
Pending legal-status Critical Current

Links

JP2023572581A 2021-05-25 2022-05-25 アルコール使用障害と診断された個体の大量飲酒軽減におけるナルトレキソンのエピジェネティックモデレータの有効性 Pending JP2024521754A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163192952P 2021-05-25 2021-05-25
US63/192,952 2021-05-25
PCT/US2022/030946 WO2022251375A2 (en) 2021-05-25 2022-05-25 Epigenetic moderators of naltrexone efficacy efficacy in reducing heavy drinking in individuals diagnosed with alcohol use disorder

Publications (3)

Publication Number Publication Date
JP2024521754A JP2024521754A (ja) 2024-06-04
JPWO2022251375A5 JPWO2022251375A5 (https=) 2025-06-02
JP2024521754A5 true JP2024521754A5 (https=) 2026-04-27

Family

ID=84230385

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023572581A Pending JP2024521754A (ja) 2021-05-25 2022-05-25 アルコール使用障害と診断された個体の大量飲酒軽減におけるナルトレキソンのエピジェネティックモデレータの有効性

Country Status (5)

Country Link
US (1) US20220389509A1 (https=)
EP (1) EP4326904A4 (https=)
JP (1) JP2024521754A (https=)
CA (1) CA3219484A1 (https=)
WO (1) WO2022251375A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025010067A1 (en) * 2023-07-06 2025-01-09 Smith Genetics Research Llc Treatment of autonomic dysfunction resulting from opioid use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009029308A1 (en) * 2007-08-27 2009-03-05 University Of Virginia Patent Foundation Medication combinations for the treatment of alcoholism and drug addiction
US20090307179A1 (en) * 2008-03-19 2009-12-10 Brandon Colby Genetic analysis
US8815779B2 (en) * 2009-09-16 2014-08-26 SwitchGear Genomics, Inc. Transcription biomarkers of biological responses and methods
US20120142543A1 (en) * 2010-11-29 2012-06-07 Kenneth Blum Methods to assess treatment outcomes in Reward Deficiency Syndrome (RDS) behaviors utilizing expression profiling
US20140274763A1 (en) * 2013-03-15 2014-09-18 Pathway Genomics Corporation Method and system to predict response to pain treatments
US20180369238A1 (en) * 2017-06-23 2018-12-27 Musc Foundation For Research Development Dopamine agonists in treating alcohol use disorders associated with dopamine receptor activity
US20180371542A1 (en) * 2017-06-26 2018-12-27 Musc Foundation For Research Development Opioid receptor blockade in treating alcohol use disorders

Similar Documents

Publication Publication Date Title
Goossens et al. Simultaneous mutation and copy number variation (CNV) detection by multiplex PCR–based GS‐FLX sequencing
JP2010528590A5 (https=)
CN116837104A (zh) 与绵羊免疫性状相关的分子标记及其应用
CN102808030B (zh) 单核苷多态性rs3888188在检测结核病易感性中的应用
JP2021100932A (ja) Ｃｒｈｒ１拮抗薬を用いた治療に対する反応の遺伝子予測因子を用いた治療の方法
JP2023552199A (ja) コロナウイルス感染症を発症するリスクが高い対象を特定する方法及びその治療法
JP2024521754A5 (https=)
JP7729608B2 (ja) 膀胱癌治療におけるｂｃｇ膀胱内注入療法の治療効果を予測するためのバイオマーカー、方法、キット及びアレイ
CN109811047A (zh) 用于检测川崎氏病的方法及套组以及用于治疗川崎氏病的方法
CN110734974B (zh) 一种癌症化疗用药snp位点组合以及检测引物
MacLaren et al. Cerebellar gene expression profiling and eQTL analysis in inbred mouse strains selected for ethanol sensitivity
WO2007144874A1 (en) Rgs2 genotypes associated with extrapyramidal symptoms induced by antipsychotic medication
CN110029162B (zh) 一种用于检测系统性红斑狼疮易感性位于非编码基因区的snp标志物及其应用
JPWO2020154268A5 (https=)
MacLaren et al. Expression profiling identifies novel candidate genes for ethanol sensitivity QTLs
JP4842256B2 (ja) 遺伝子一塩基多型解析によるアトピー性皮膚炎の相対罹患危険率の検出方法
Javor et al. The+ 190 G/A (rs1799864) polymorphism in the C–C chemokine receptor 2 (CCR2) gene is associated with susceptibility to multiple sclerosis in HLA-DRB1* 15: 01-negative individuals
KR101724130B1 (ko) 장 베체트병 진단용 바이오마커 및 이의 용도
KR100707196B1 (ko) 특정 질병 또는 약물 감수성 관련 다중 단일염기다형의스크리닝 방법
JP5787337B2 (ja) Ｃ型肝炎の治療効果を予測するためのマーカー群、検査方法及び検査用キット
CN108251519B (zh) 轴前多指病的致病基因及其用途
Chen et al. Characterization of the novel HLA‐C* 06: 02: 96 allele by next‐generation sequencing.
KR102281644B1 (ko) 지연성 허혈 진단을 위한 insr 유전자 과메틸화 마커
WO2011138370A1 (en) Antiviral treatment susceptibility gene and uses thereof
KR102281657B1 (ko) 지연성 허혈 진단을 위한 cdhr5 유전자 과메틸화 마커